What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience

详细信息    查看全文

• 作者：H. Findlow ; R. Borrow
• 刊名：Pediatric Drugs
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：18
• 期：2
• 页码：83-87
• 全文大小：399 KB
• 参考文献：1.EU IBIS. http://​www.​hpa-bioinformatics.​org.​uk/​euibis/​meningo/​vacc_​sched_​meningo.​htm . Accessed 26 Aug 2015.
  2.Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365–6.CrossRef PubMed PubMedCentral
  3.Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569–72.CrossRef PubMed
  4.Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840–7.CrossRef PubMed PubMedCentral
  5.Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K, Miller E. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis. 2002;186:1353–7.CrossRef PubMed
  6.Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745–52.CrossRef PubMed
  7.Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, Stapley L, England A, Findlow J, Miller E. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccin Immunol. 2010;17:154–9.CrossRef
  8.PHE. https://​www.​gov.​uk/​government/​uploads/​system/​uploads/​attachment_​data/​file/​463955/​hpr3415_​IMD.​pdf . Accessed 7 Oct 2015.
  9.Cartwright KAV, Stuart JM, Jones DM, Noah ND. The Stonehouse Survey. Epidemiol Infect. 1987;99:591–601.CrossRef PubMed PubMedCentral
  10.Ala’aldeen DA, Oldfield NJ, Bidoms FA, Abouseada NM, Ahmed NW, Turner DP, Neal KR, Bayliss CD. Carriage of meningococci by university students, United Kindgom. Emerg Infect Dis. 2011;17:1762–1763.
  11.Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, Ala’aldeen DA, Crook DW, Cann K, Harrison S, Cunningham R, Baxter D, Kaczmarski E, MacLennan J, Cameron JC, Stuart JM. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–43.CrossRef PubMed
  12.Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, Miller E. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694–8.CrossRef PubMed PubMedCentral
  13.Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19:1126–30.CrossRef PubMed PubMedCentral
  14.Findlow H, Borrow R, Andrews N, Waight P, Sheasby E, Matheson M, England A, Goldblatt D, Ashton L, Findlow J, Miller E. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatr Infect Dis J. 2012;31:616–22.CrossRef PubMed
  15.Department of Health/Public Health England. Changes to the schedule for meningococcal serogroup C conjugate vaccine 7 May 2013.
  16.de Whalley PC, Snape MD, Plested E, Thompson B, Nuthall E, Omar O, Borrow R, Pollard AJ. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child. 2013;98:686–91.CrossRef PubMed
  17.PHE Health Protection Report, Volume 9 number 7. https://​www.​gov.​uk/​government/​uploads/​system/​uploads/​attachment_​data/​file/​407865/​hpr0715_​men-w.​pdf . Accessed 7 Oct 2015.
  18.Hahné SJ, Gray SJ, Jean-François, Aguilera, Crowcroft NS, Nichols T, Kaczmarski EB, Ramsay ME. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet. 2002;359:582–583.
  19.Ibarz-Pavon AB, Lemos AP, Gorla MC, Regueira M; SIREVA Working Group II, Gabastou JM. Laboatory based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006–2010. Plos One 2012;7:e 44102.
  20.Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142:2461–70.CrossRef PubMed
  21.Valenzueka MT, Moreno G, Vaquero A, Seoane M, Hormazábal JC, Bertoglia MP, Gallegos D, Sotomayor V, Díaz J. Emergence of W135 meningococcal serogroup in Chile during 2012. Med Rev Chile. 2013;141:959–67.CrossRef
  22.Lucidarme J, Hill DMC, Bratcher HB, Gray SJ, du Plessis M, Tsang RSW, Vazquez JA, Taha MK, Ceyhan M, Efron AM, Gorla MC, Findlow J, Jolley KA, Maiden MCJ, Borrow R. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal B. C and W lineage. J Infect. 2015;71:544–52.CrossRef PubMed PubMedCentral
  23.PHE and NHS England (2015). Meningococcal ACWY conjugate vaccination (MenACWY) (bipartite letter), 22 June.
  24.Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;13(384):2123–31.CrossRef
  25.Ishola DA, Andrews N, Waight P, Yung CF, Southern J, Bai X, Findlow H, Matheson M, England A, Hallis B, Findlow J, Borrow R, Miller E. Randomized trial to compare the immunogenicity and safety of a CRM or TT conjugated quadrivalent meningococcal vaccine in teenagers who received a CRM or TT conjugated serogroup C vaccine at preschool age. Pediatr Infect Dis J. 2015;34:865–74.CrossRef PubMed
  
• 作者单位：H. Findlow (1)
  R. Borrow (1) (2)
  
  1. Vaccine Evaluation Unit, Public Health England, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
  2. University of Manchester, Inflammation Sciences Research Group, School of Translational Medicine, Stopford Building, Manchester, UK
  
• 刊物主题：Pediatrics; Pharmacotherapy; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-2019

文摘

Meningococcal disease is a major global public health problem, and vaccination is the optimal means of prevention. Meningococcal vaccination programmes have significantly evolved, for example, in the UK, since their introduction in 1999. The UK, the first country to introduce meningococcal serogroup C conjugate (MCC) vaccination, commenced this in 1999 with a primary infant series at 2, 3 and 4 months of age, together with a catch-up campaign of a single dose for children aged 1–18 years. Subsequent changes to the schedule have occurred in response to increasing knowledge about how MCC vaccines work, together with improved knowledge of meningococcal transmission. Firstly, in 2006, the schedule was refined from a three-dose to a two-dose priming schedule with the addition of a booster in the second year of life. This was followed by a further change in 2013, when the number of priming doses was further reduced to a single priming dose along with a booster maintained at 12 months of age and the introduction of an adolescent MCC booster dose. This in 2015 was changed from monovalent serogroup C to quadrivalent A, C, W and Y in response to an outbreak of serogroup W.